Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K7 | O14733 | 1/20 | 0.45 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.36 |
| ▸ | FPR3 | P25089 | 2/20 | 0.36 |
| ▸ | TSPO | P30536 | 2/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039739 | 1.00 | MAP2K7 (0.45) | MAP2K7CRHR1FPR3TSPOTMEM97 | |
| Hydrochloric Acid SCHEMBL1637180 | 0.99 | MAP2K7 (0.44) | MAP2K7CRHR1FPR3TSPOTMEM97 | |
| SCHEMBL1637091 | 0.96 | MAP2K7 (0.42) | MAP2K7CRHR1FPR3TSPOTMEM97 | |
| SCHEMBL1636245 | 0.93 | MAP2K7 (0.44) | MAP2K7CRHR1FPR3TSPOTMEM97 | |
| SCHEMBL1636814 | 0.92 | MAP2K7 (0.37) | MAP2K7CRHR1FPR3TSPOTMEM97 | |
| SCHEMBL1636114 | 0.91 | MAP2K7 (0.46) | MAP2K7CRHR1FPR3TSPOTMEM97 | |
| Hydrochloric Acid SCHEMBL1638286 | 0.91 | MAP2K7 (0.37) | MAP2K7CRHR1FPR3TSPOTMEM97 | |
| SCHEMBL1637146 | 0.91 | MAP2K7 (0.43) | MAP2K7CRHR1CHRM3PDE4APDE4B | |
| SCHEMBL12593337 | 0.90 | CRHR1 (0.39) | MAP2K7CRHR1FPR3TSPOTMEM97 | |
| SCHEMBL1638289 | 0.90 | MAP2K7 (0.42) | MAP2K7CRHR1FPR3TSPOTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026047334-A1 | MC2R MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2026-03-05 | — | — | WO | disclosed |
| EP-4450070-A1 | CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2024175927-A1 | MC2R MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024175925-A1 | MC2R MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024175928-A1 | MC2R MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-08-29 | — | — | WO | disclosed |
| EP-3096756-B1 | CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | NEUROCRINE BIOSCIENCES INC (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20240058342-A1 | TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | NEUROCRINE BIOSCIENCES, INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2023163945-A1 | TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA AND POLYCYSTIC OVARY SYNDROME | Crinetics Pharmaceuticals, Inc. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-11730739-B2 | Treatment of congenital adrenal hyperplasia | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11311544-B2 | Treatment of congenital adrenal hyperplasia | NEUROCRINE BIOSCIENCES, INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730739-B2 | Treatment of congenital adrenal hyperplasia | CRHR1, MC2R, CRH | MAP2K7 1592/4885CRHR1 1/4885FPR3 899/4885 |
| US-11311544-B2 | Treatment of congenital adrenal hyperplasia | CRHR1, MC2R, CRH | MAP2K7 1592/4885CRHR1 1/4885FPR3 899/4885 |
| US-20240058342-A1 | TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | CRHR1, MC2R, CRH | MAP2K7 1592/4885CRHR1 1/4885FPR3 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.